Short Bowel Syndrome (SBS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Short Bowel Syndrome (SBS) Market Outlook

Thelansis’s “Short Bowel Syndrome (SBS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Short Bowel Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Short Bowel Syndrome (SBS) Overview

Short bowel syndrome (SBS) is a condition marked by reduced digestive and absorptive capabilities, often stemming from surgical removal, congenital defects, or bowel diseases. This absorption deficiency leads to nutritional and electrolyte imbalances. In adults, SBS is typically defined as having less than 180 to 200 centimeters of remaining small bowel (in contrast to the normal range of 275 to 850 cm), necessitating nutritional and fluid supplementation. Patients exhibit malabsorption-related symptoms like weight loss, diarrhea, steatorrhea, dehydration, malnutrition, and electrolyte disturbances. SBS is an uncommon malabsorptive disorder primarily caused by extensive surgical small intestine resection, resulting in significant morbidity, mortality, and a reduced quality of life. Parenteral nutrition is generally unnecessary for those with over 180 cm of small bowel. Those with over 90 cm may require it for less than a year, while those with less than 60 cm will likely need lifelong parenteral nutrition.

• According to Thelansis disease modeling and literature reviews, the estimated prevalence of SBS in the USA ranges between 22.5 and 33 cases per million population.
• SBS affects approximately 15% of adult patients who undergo intestinal resection, with up to 75% of cases attributed to extensive intestinal resection and 25% to multiple sequential resections.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: